Equity research analysts tracking Compass Therapeutics (CMPX) note promising clinical data in oncology pipelines and a healthy cash runway, but note that pre-revenue biotech investments carry inherent clinical trial risks. To help evaluate this option: What is your total risk tolerance, and what percentage of your portfolio do you allocate to clinical-stage biopharmaceuticals?